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euroﬁbromatosis  type  2  (NF2)  is  a  rare  disease,  charac-
erized  by  a  mutation  in  the  long  arm  of  chromosome
2  that  leads  to  the  development  of  bilateral  vestibular
chwannomas  (VS)  in  approximately  90%  of  patients  with  this
yndrome.1--4
The  control  of  tumor  growth  and  hearing  preservation  are
he  cornerstones  of  its  treatment,  which  can  be  carried  out
y  surgery  or  radiotherapy,  considering  the  size  of  the  lesion
nd  the  presence  of  functional  hearing.
The  possibilities  of  hearing  rehabilitation  range  from  the
daptation  of  conventional  hearing  aids  (HA)  to  auditory
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ccess article under the CC BY license (http://creativecommons.org/licrainstem  implant  (ABI).  In  the  latter  case,  hearing  results
re  limited,  because  this  procedure  only  enables  the  detec-
ion  of  sound  and  acts  as  an  auxilliary  for  lip  reading.  Thus,
everal  authors  consider  microsurgery  with  preservation  of
he  cochlear  nerve  and  use  of  a  cochlear  implant  as  the  best
herapeutic  option.3--6
ase report
MC,  a  50-year-old  male  with  progressive  bilateral  hearing
oss  for  2  years,  related  recent  dizziness,  bilateral  tinni-
us  and  headache.  At  physical  examination,  this  patient
evealed  normal  otoscopy,  no  nystagmus  and  a  positive  sen-
itized  Romberg  test  with  deviation  to  the  right;  no  changes
ere  observed  in  other  cranial  nerves.
Audiometry  revealed  bilateral  sensorineural  hearing  loss
43  dB  for  the  right  ear  and  >80  dB  for  the  left  ear)  and  the
uditory  brainstem  evoked  potential  was  absent  in  the  left
ar.  Magnetic  resonance  imaging  (MRI)  showed  solid  lesions
ith  irregular  borders  occupying  the  inside  of  both  internal
uditory  canals  (Fig.  1).
a Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open
enses/by/4.0/).
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Figure  1  T2-weighted  axial  MRI  before  radiotherapy,  showing  an  expansive  lesion  measuring  1.0  cm  ×  0.7  cm  ×  0.7  cm  and  occupy-
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5ing the  right  internal  auditory  canal  (T1  according  to  the  classiﬁ
2.0 cm  ×  1.2  cm  ×  0.7  cm  on  the  left  (Hannover  T3a).
At  that  time,  it  was  suggested  left  tumor  surgical
removal;  however,  given  the  patient’s  refusal,  our  decision
was  for  bilateral  fractionated  stereotactic  radiotherapy  and
use  of  hearing  aids.
A  year  after  radiotherapy,  even  with  the  tumor  under
control,  our  patient  developed  progression  of  his  hearing
impairment  to  left  anacusis  and  severe  right  sensorineural
hearing  loss  (threshold,  80  dB),  with  30%  discrimination  of
sentences  in  an  open  context  using  bilateral  hearing  aids.
Thus,  a  right-ear  cochlear  implant  ear  was  recommended,
due  to  its  smaller  tumor  and  a  residual  hearing.  Twelve
months  after  implantation,  the  patient  discriminates  100%
of  Ling’s  six-sound  test,  monosyllables,  vowels  and  sen-
tences  in  an  open  context.
Discussion
The  ﬁrst  cochlear  implant  after  surgical  removal  of  VC
was  reported  in  1992.  A  decade  later,  we  found  in  our
search  reports  of  37  patients  who  underwent  complete
resection  of  VS,  combined  with  a  cochlear  implant,  with
possibility  of  discrimination  in  an  open  context  in  68%  of
cases.5
In  2013,  a  Belgian  study  related  hearing  preservation
with  radiosurgery  in  the  treatment  of  NF2  in  a  series  of
12  patients,  and  78%  had  functional  hearing  (discrimination
>70%)  up  to  2  years  after  radiation.  However,  it  is  important
to  point  out  that  hearing  impairment  can  happen  even  after
several  years,  due  to  a  degeneration  of  the  stria  vascularis
secondary  to  radiation.6
In  2010,  Trotter  et  al.  published  the  results  of  cochlear
implants  in  two  patients  with  NF2  submitted  to  radiothe-
rapy  in  the  ear  that  received  the  implant.  One  of  these
patients  reached  96%  of  discrimination  of  sentences,  and
the  other,  72%.  A  systematic  review  carried  out  in  2012
showed  that  among  eight  patients  with  NF2  and  deafness
treated  with  radiosurgery,  six  achieved  discrimination  sen-
tences  in  an  open  context  with  the  use  of  a  cochlear
implant.4,6
6n  of  Hannover)  and  another  injury  of  the  same  kind  measuring
In  our  case,  the  patient  with  NF2  underwent  fractioned
tereotactic  radiotherapy  and  a  cochlear  implant  after
umor  control;  one  year  after  implantation,  this  patient
howed  good  results,  being  able  to  understand  well  what
s  spoken  in  a  spontaneous  conversation,  denoting  a  good
omprehension  of  speech  and  of  its  suprasegmentar  traits,
uch  as  rhythm  and  intonation.
inal comments
he  use  of  a  cochlear  implant  in  patients  with  NF2  treated
ith  radiotherapy  is  still  a scarcely  reported  auditory  reha-
ilitation  strategy,  but  that  has  proven  effective,  as  in  the
resent  case.
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